Works matching AU Verbeke, Geert

Results: 167
    1
    2
    3
    4
    5
    6

    Conditional mixed models with crossed random effects.

    Published in:
    British Journal of Mathematical & Statistical Psychology, 2007, v. 60, n. 2, p. 351, doi. 10.1348/000711006X110562
    By:
    • Tibaldi, Fabian S.;
    • Verbeke, Geert;
    • Molenberghs, Geert;
    • Renard, Didier;
    • Noortgate, Wim;
    • Boeck, Paul
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Role for Granulocyte Colony‐Stimulating Factor in Neutrophilic Extramedullary Myelopoiesis in a Murine Model of Systemic Juvenile Idiopathic Arthritis.

    Published in:
    Arthritis & Rheumatology, 2022, v. 74, n. 7, p. 1257, doi. 10.1002/art.42104
    By:
    • Malengier‐Devlies, Bert;
    • Bernaerts, Eline;
    • Ahmadzadeh, Kourosh;
    • Filtjens, Jessica;
    • Vandenhaute, Jessica;
    • Boeckx, Bram;
    • Burton, Oliver;
    • De Visscher, Amber;
    • Mitera, Tania;
    • Berghmans, Nele;
    • Verbeke, Geert;
    • Liston, Adrian;
    • Lambrechts, Diether;
    • Proost, Paul;
    • Wouters, Carine;
    • Matthys, Patrick
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial.

    Published in:
    Trials, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s13063-021-05033-x
    By:
    • Gyselinck, Iwein;
    • Liesenborghs, Laurens;
    • Landeloos, Ewout;
    • Belmans, Ann;
    • Verbeke, Geert;
    • Verhamme, Peter;
    • Vos, Robin;
    • Janssens, W.;
    • on behalf of the DAWn-Azithro consortium;
    • Janssens, Wim;
    • Vanderhelst, Eef;
    • Bouckaert, Bernard;
    • Alexander, Patrick;
    • De Mayer, Nikolaas;
    • Papleux, Emmanuelle;
    • Soenen, Ann-Catherine;
    • Derweduwe, Aurelie;
    • Vandeurzen, Kurt;
    • Martinot, Jean-Benoît;
    • Goeminne, Pieter
    Publication type:
    Article
    43
    44

    Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.

    Published in:
    2020
    By:
    • Devos, Timothy;
    • Geukens, Tatjana;
    • Schauwvlieghe, Alexander;
    • Ariën, Kevin K.;
    • Barbezange, Cyril;
    • Cleeren, Myriam;
    • Compernolle, Veerle;
    • Dauby, Nicolas;
    • Desmecht, Daniël;
    • Grimaldi, David;
    • Lambrecht, Bart N.;
    • Luyten, Anne;
    • Maes, Piet;
    • Moutschen, Michel;
    • Romano, Marta;
    • Seyler, Lucie;
    • Nevessignsky, Michel Toungouz;
    • Vandenberghe, Katleen;
    • van Griensven, Johan;
    • Verbeke, Geert
    Publication type:
    corrected article
    45

    A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

    Published in:
    Trials, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s13063-020-04876-0
    By:
    • Devos, Timothy;
    • Geukens, Tatjana;
    • Schauwvlieghe, Alexander;
    • Ariën, Kevin K.;
    • Barbezange, Cyril;
    • Cleeren, Myriam;
    • Compernolle, Veerle;
    • Dauby, Nicolas;
    • Desmecht, Daniël;
    • Grimaldi, David;
    • Lambrecht, Bart N.;
    • Luyten, Anne;
    • Maes, Piet;
    • Moutschen, Michel;
    • Romano, Marta;
    • Seyler, Lucie;
    • Nevessignsky, Michel Toungouz;
    • Vandenberghe, Katleen;
    • van Griensven, Johan;
    • Verbeke, Geert
    Publication type:
    Article
    46

    A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.

    Published in:
    Trials, 2020, v. 21, n. 1, p. N.PAG, doi. 10.1186/s13063-020-04876-0
    By:
    • Devos, Timothy;
    • Geukens, Tatjana;
    • Schauvlieghe, Alexander;
    • Ariën, Kevin K.;
    • Barbezange, Cyril;
    • Cleeren, Myriam;
    • Compernolle, Veerle;
    • Dauby, Nicolas;
    • Desmecht, Daniël;
    • Grimaldi, David;
    • Lambrecht, Bart N.;
    • Luyten, Anne;
    • Maes, Piet;
    • Moutschen, Michel;
    • Romano, Marta;
    • Seyler, Lucie;
    • Nevessignsky, Michel Toungouz;
    • Vandenberghe, Katleen;
    • van Griensven, Johan;
    • Verbeke, Geert
    Publication type:
    Article
    47
    48
    49
    50